cyclophosphamide + fluorouracil + pirarubicin + vindesine

This is a combination chemotherapy regimen consisting of four cytotoxic agents: - Cyclophosphamide, an alkylating agent that crosslinks DNA, leading to cell death. - Fluorouracil (5-FU), an antimetabolite that inhibits thymidylate synthase and disrupts DNA synthesis. - Pirarubicin, an anthracycline antibiotic similar to doxorubicin/adriamycin, which intercalates into DNA and inhibits topoisomerase II. - Vindesine, a vinca alkaloid that inhibits microtubule assembly and arrests cells in metaphase. This combination is not a standard named regimen but represents a multi-agent protocol designed for the treatment of various cancers—most commonly breast cancer or other solid tumors. Each component has established use in oncology as part of different regimens. The mechanism of action involves multiple pathways targeting rapidly dividing tumor cells through DNA damage, inhibition of nucleotide synthesis, interference with mitosis, and disruption of topoisomerase function.